Pseudoexfoliation Syndrome
Definition
A systemic fibrillopathy characterized by production and accumulation of abnormal extracellular fibrillar material in the anterior segment and throughout the body, associated with elevated IOP, glaucoma, and zonular weakness.
Clinical Snapshot
Pseudoexfoliation syndrome (PXF) is a systemic fibrillopathy in which abnormal extracellular fibrillar material (pseudoexfoliative material) is produced and deposited throughout the body — most visibly in the anterior segment of the eye. It is the most common identifiable cause of secondary open-angle glaucoma worldwide. PXF glaucoma is more aggressive than POAG — higher IOP, greater IOP fluctuation, and faster progression. Zonular weakness is a critical surgical consideration.
Epidemiology
PXF prevalence increases dramatically with age — rare before 50, affecting up to 25% of adults over 75 in some populations. It is particularly prevalent in Scandinavian, Mediterranean, and Middle Eastern populations. Approximately 25–40% of PXF patients develop glaucoma.
Pathophysiology
Pseudoexfoliative material is an abnormal extracellular matrix protein aggregate produced by abnormal basement membrane metabolism in multiple cell types. In the eye, it deposits on the lens capsule (classic "bull's eye" pattern), zonular fibers, ciliary body, trabecular meshwork, and corneal endothelium. Trabecular meshwork obstruction by PXF material and pigment causes IOP elevation. Zonular fiber involvement causes progressive zonular weakness, increasing the risk of lens subluxation and complications during cataract surgery.
Risk Factors
- Advanced age
- Scandinavian, Mediterranean, or Middle Eastern ancestry
- Family history of PXF
- LOXL1 gene variants (the primary genetic risk factor)
Clinical Presentation
The classic sign is the "bull's eye" pattern of PXF material on the anterior lens capsule — a central disc, a clear zone, and a peripheral granular zone. Pupillary ruff loss, peripupillary transillumination defects, and PXF material on the pupillary margin are additional signs. Gonioscopy reveals trabecular meshwork pigmentation (often unilateral or asymmetric) and Sampaolesi's line. IOP is often elevated and asymmetric.
Diagnostic Pearls
- Dilate the pupil to visualize the classic bull's eye pattern on the anterior lens capsule — it is not visible through an undilated pupil.
- PXF is frequently unilateral or markedly asymmetric — compare both eyes carefully.
- Gonioscopy reveals Sampaolesi's line (pigment anterior to Schwalbe's line) — a characteristic finding.
- Assess zonular integrity before cataract surgery — PXF significantly increases the risk of zonular dialysis and vitreous loss.
Differential Diagnosis
- Primary open-angle glaucoma
- Pigmentary glaucoma
- True exfoliation (from heat/infrared exposure)
Evidence-Based Management
PXF without glaucoma: monitor IOP and optic nerve closely — conversion to glaucoma is common. PXF glaucoma: IOP-lowering therapy as for POAG, but more aggressive targets are appropriate given the higher progression risk. Prostaglandin analogues are first-line. Laser trabeculoplasty is effective in PXF. Surgical intervention is often required earlier than in POAG. Cataract surgery requires careful planning for zonular weakness.
Monitoring & Follow-Up
More frequent monitoring than POAG — IOP fluctuation is greater and progression is faster. Biannual visual fields and OCT RNFL are appropriate for established PXF glaucoma.
Clinical Pearls
- PXF glaucoma is more aggressive than POAG — set lower IOP targets and monitor more frequently.
- Zonular weakness is a critical surgical consideration — alert the cataract surgeon to PXF before any intraocular surgery.
- IOP fluctuation is a major feature of PXF — diurnal IOP curves may reveal spikes not captured at routine visits.
- PXF is a systemic condition — associations with cardiovascular disease and Alzheimer's disease have been reported.
Related Therapeutics — Clinician's Companion
- Glaucoma Therapeutics — Prostaglandins, Beta-blockers (Clinician's Companion)
Key References
- 1.Ritch R, Schlötzer-Schrehardt U. Exfoliation syndrome. Surv Ophthalmol. 2001.
- 2.Thorleifsson G, et al. Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. Science. 2007.
This entry is an educational reference designed to support clinical reasoning and awareness. It does not constitute medical advice, establish a standard of care, or replace individualized patient assessment. Clinicians should consult current guidelines and applicable clinical resources when making patient care decisions.